Who Exports Regorafenib from India — 60 Suppliers Behind a $1.0M Market

Hyderabad, often referred to as India's "Bulk Drug Capital," is a central hub for the production of active pharmaceutical ingredients (APIs). The city hosts numerous API manufacturers and has a well-established infrastructure for bulk drug production. Notably, a manufacturer established in 2013 specializes in oncology, focusing on the research, manufacturing, and marketing of high-quality specialty formulations, including Regorafenib tablets. This manufacturer operates a state-of-the-art facility in Hyderabad, designed to meet global regulatory requirements, and holds GMP certifications from international regulatory authorities, including USFDA, MHRA, and PIC/S.

The Ahmedabad-Vadodara corridor in Gujarat is renowned for its focus on pharmaceutical formulations. This region is home to major pharmaceutical companies such as Cadila Pharmaceuticals and Zydus Lifesciences, both headquartered in Ahmedabad. Cadila Pharmaceuticals, established in 1951, has grown to become one of the largest vaccine manufacturers in India. Zydus Lifesciences, formerly known as Cadila Healthcare Limited, is an Indian multinational pharmaceutical company primarily engaged in the manufacturing of generic drugs. The presence of these industry leaders underscores the region's capacity for high-quality pharmaceutical production, making it a strategic location for the formulation of drugs like Regorafenib.

The Mumbai-Thane-Raigad belt serves as a critical export gateway for India's pharmaceutical products. Mumbai, being a major port city, facilitates the efficient export of pharmaceuticals to global markets. The region's well-developed logistics and proximity to international shipping routes enhance its role in the global pharmaceutical supply chain. Companies operating in this area benefit from streamlined export processes, making it an advantageous location for distributing products like Regorafenib to international destinations.

Baddi-Nalagarh, located in Himachal Pradesh, is recognized as Asia's largest pharmaceutical hub. The region houses over 3,120 factories belonging to leading pharma, FMCG, and textile companies, generating an annual turnover of Rs 60,000 crore. Baddi employs one-third of all persons engaged in Himachal's medium and large industries and contributes half of the state's total revenues generated from industries. The established manufacturing infrastructure and skilled workforce make Baddi-Nalagarh a viable option for pharmaceutical production.

• Evaluate API Suppliers in Hyderabad: Given Hyderabad's status as a bulk drug capital, sourcing Regorafenib APIs from this region could ensure quality and cost-effectiveness.

• Consider Formulation Partners in Ahmedabad-Vadodara: Collaborating with formulation specialists in this corridor can leverage their expertise in producing high-quality pharmaceutical products.

• Utilize Mumbai's Export Infrastructure: For efficient international distribution, partnering with firms in the Mumbai-Thane-Raigad region can streamline export processes.

• Assess Manufacturing Facilities in Baddi-Nalagarh: Exploring production opportunities in this hub may offer advantages due to its established pharmaceutical manufacturing ecosystem.

By strategically engaging with these pharmaceutical clusters, companies can optimize their supply chain for Regorafenib, ensuring quality production and efficient distribution to meet global demand.